Skip to search formSkip to main contentSkip to account menu

abarelix

Known as: N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(6)-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, abarelix [Chemical/Ingredient] 
A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Hormone AntagonistsOligopeptides

Narrower (2)

PPI-149Plenaxis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Utility of LHRH antagonists for advanced prostate cancer.
INTRODUCTION Androgen deprivation therapy (ADT) is the lynchpin of treatment for advanced prostate cancer. Prescribing physicians… 
2012
2012
New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone‐releasing hormone agonist
Study Type – Therapy (prospective cohort) 
2012
2012
Prostate cancer: Making the switch from LHRH antagonist to LHRH agonist
One very important issue faced by clinicians managing patients with prostate cancer is whether after initiating a man on a pure… 
2012
2012
NEW TREATMENT PARADIGM FOR PROSTATE CANCER: ABARELIX INITIATION THERAPY FOR IMMEDIATE TESTOSTERONE SUPPRESSION FOLLOWED BY A LUTEINIZING HORMONE‐RELEASING HORMONE AGONIST
Sir, On the 16 November 2011, the online version of BJU International reported on the results of a prospective open-labelled… 
Review
2010
Review
2010
GnRH antagonists in the treatment of advanced prostate cancer.
Analogues of the gonadotropin releasing hormone (GnRH) inhibit the hypothalamic-pituitary-gonadal axis. This has provided… 
2008
2008
Management of advanced prostate cancer: gonadotropin-releasing hormone blockers might improve prognosis.
2006
2006
Discovery of a pituitary adenoma following a gonadotropin‐releasing hormone agonist in a patient with prostate cancer
Abstract  Gonadotropin‐releasing hormone (GnRH) agonists have become the treatment of choice for locally advanced and metastatic… 
2006
2006
Unnatural D-amino acids as building blocks of new peptidomimetics.
offers many advantages as newly designed drugs. The benefits include enhanced stability to proteolytic enzymes, better transport… 
2005
2005
Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer.
2001
2001
The evolution of hormonal therapy for prostatic carcinoma.
It is well recognized that testosterone has a number of untoward effects on prostatic carcinoma and that castration is associated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)